Eli Lilly’s pipeline promises you big returns

Article Excerpt

We think the drug industry will enjoy great success over the next decade. But due to the nature of the business, results will vary widely and unpredictably from one drug company to another. A volatile market like the one we expect for drug stocks will include winners and losers. Here is one that we expect to be among the big winners. We recommend this stock as a Power Buy. ELI LILLY & CO., $275.28, (New York symbol LLY; TSINetwork Rating: Above Average) (www.lilly.com; Shares outstanding: 956.6 million; Market cap: $238.6 billion; Dividend yield: 1.4%) discovers, develops, manufactures, and markets human pharmaceutical products. Eli Lilly narrowed its focus in March 2019 when it spun off its Elanco Animal Health business. Elanco (symbol ELAN on New York) makes medications for both livestock and companion animals (pets). The Elanco spinoff was among the biggest strategic decisions by CEO Dave Ricks in his restructuring of Lilly. Since Ricks assumed the position at the start of 2017, he has overseen the company’s withdrawal from…